{"id":742301,"date":"2013-10-22T16:00:00","date_gmt":"2013-10-22T16:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\/"},"modified":"2023-03-22T00:04:33","modified_gmt":"2023-03-22T04:04:33","slug":"merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\/","title":{"rendered":"Merck Receives Breakthrough Therapy Designation for MK-5172\/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that the U.S. Food and Drug Administration (FDA) has<br \/>\n      granted MK-5172\/MK-8742 Breakthrough Therapy designation for treatment<br \/>\n      of chronic hepatitis C virus infection. MK-5172\/MK-8742 is an all-oral<br \/>\n      combination regimen consisting of MK-5172, an investigational HCV NS3\/4A<br \/>\n      protease inhibitor, and MK-8742, an investigational HCV NS5A replication<br \/>\n      complex inhibitor. Interim data from an ongoing Phase IIB clinical trial<br \/>\n      evaluating MK-5172\/MK-8742 in genotype 1 infected patients (C-WORTHY<br \/>\n      Study) is scheduled to be presented at the <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.aasld.org%2Flivermeeting%2Fprogram%2FPages%2Fdefault.aspx&#038;esheet=50734362&#038;newsitemid=20131022006804&#038;lan=en-US&#038;anchor=64th+American+Association+for+the+Study+of+Liver+Disease+Annual+Meeting%2C&#038;index=1&#038;md5=670a43a0cef6c1ff80240660a3b09a9a\" rel=\"nofollow\">64<sup>th<\/sup><br \/>\n      American Association for the Study of Liver Disease Annual Meeting,<\/a><br \/>\n      Washington D.C., Nov. 1-5.\n    <\/p>\n<p>\n      \u201cThe designation of MK-5172\/MK-8742 as a Breakthrough Therapy for<br \/>\n      chronic hepatitis C is an important milestone for Merck,\u201d said Dr. Roger<br \/>\n      M. Perlmutter, president, Merck Research Laboratories. \u201cThere remains<br \/>\n      significant unmet medical need in hepatitis C, and we are looking<br \/>\n      forward to working with the FDA to advance this program as quickly as we<br \/>\n      can to bring this investigational combination to HCV specialists and<br \/>\n      their patients.\u201d\n    <\/p>\n<p>\n      According to the FDA, the designation of an investigational drug as a<br \/>\n      Breakthrough Therapy is intended to expedite the development and review<br \/>\n      of a candidate that is planned for use, alone or in combination, to<br \/>\n      treat a serious or life-threatening disease or condition when<br \/>\n      preliminary clinical evidence indicates that the drug may demonstrate<br \/>\n      substantial improvement over existing therapies on one or more<br \/>\n      clinically significant endpoints.\n    <\/p>\n<p>\n      Chronic hepatitis C is a priority focus of research and development at<br \/>\n      Merck. MK-5172 and MK-8742 are being investigated in a broad clinical<br \/>\n      program that includes studies in patients with multiple HCV genotypes<br \/>\n      who are treatment-na\u00efve, treatment failures as well as other important<br \/>\n      HCV subpopulations such as patients with cirrhosis and those co-infected<br \/>\n      with HIV. For more information please see <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.clinicaltrials.gov&#038;esheet=50734362&#038;newsitemid=20131022006804&#038;lan=en-US&#038;anchor=www.clinicaltrials.gov&#038;index=2&#038;md5=c2816a40f8e0ed63ec47543c4aacce07\" rel=\"nofollow\">www.clinicaltrials.gov<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50734362&#038;newsitemid=20131022006804&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=3&#038;md5=b8c6ec418484650f567b959eaf056f48\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2FMerck&#038;esheet=50734362&#038;newsitemid=20131022006804&#038;lan=en-US&#038;anchor=Twitter&#038;index=4&#038;md5=c74ab4097da19156dfc8de161fe57f0d\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50734362&#038;newsitemid=20131022006804&#038;lan=en-US&#038;anchor=Facebook&#038;index=5&#038;md5=d813c64fa1064ce462e71726019ce1cd\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50734362&#038;newsitemid=20131022006804&#038;lan=en-US&#038;anchor=YouTube&#038;index=6&#038;md5=edafbbb8285fd52bfa54d2a801117d3c\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50734362&#038;newsitemid=20131022006804&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=7&#038;md5=9ee854f463e36b453341d9d7b91d298d\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20131022006804r1&#038;sid=hq1sf1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Pamela Eisele, 908-423-5042<br \/>Sarra        Herzog, 908-423-6154<br \/>or<br \/>Investor Contacts:<br \/>Carol        Ferguson, 908-423-4465<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted MK-5172\/MK-8742 Breakthrough Therapy designation for treatment of chronic hepatitis C virus infection. MK-5172\/MK-8742 is an all-oral combination regimen consisting of MK-5172, an investigational HCV NS3\/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor. Interim data from an ongoing Phase IIB clinical trial evaluating MK-5172\/MK-8742 in genotype 1 infected patients (C-WORTHY Study) is scheduled to be presented at the 64th American Association for the Study of Liver Disease Annual Meeting, Washington D.C., Nov. 1-5. \u201cThe designation of MK-5172\/MK-8742 as a Breakthrough Therapy for chronic hepatitis C is an important milestone for Merck,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cThere remains significant unmet medical need in hepatitis C, and we are looking forward to<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-742301","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Receives Breakthrough Therapy Designation for MK-5172\/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Receives Breakthrough Therapy Designation for MK-5172\/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted MK-5172\/MK-8742 Breakthrough Therapy designation for treatment of chronic hepatitis C virus infection. MK-5172\/MK-8742 is an all-oral combination regimen consisting of MK-5172, an investigational HCV NS3\/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor. Interim data from an ongoing Phase IIB clinical trial evaluating MK-5172\/MK-8742 in genotype 1 infected patients (C-WORTHY Study) is scheduled to be presented at the 64th American Association for the Study of Liver Disease Annual Meeting, Washington D.C., Nov. 1-5. \u201cThe designation of MK-5172\/MK-8742 as a Breakthrough Therapy for chronic hepatitis C is an important milestone for Merck,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cThere remains significant unmet medical need in hepatitis C, and we are looking forward to\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:33+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131022006804r1&sid=hq1sf1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\\\/\",\"name\":\"Merck Receives Breakthrough Therapy Designation for MK-5172\\\/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131022006804r1&sid=hq1sf1&distro=nx\",\"datePublished\":\"2013-10-22T16:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131022006804r1&sid=hq1sf1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131022006804r1&sid=hq1sf1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Receives Breakthrough Therapy Designation for MK-5172\\\/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Receives Breakthrough Therapy Designation for MK-5172\/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\/","og_locale":"en_US","og_type":"article","og_title":"Merck Receives Breakthrough Therapy Designation for MK-5172\/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted MK-5172\/MK-8742 Breakthrough Therapy designation for treatment of chronic hepatitis C virus infection. MK-5172\/MK-8742 is an all-oral combination regimen consisting of MK-5172, an investigational HCV NS3\/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor. Interim data from an ongoing Phase IIB clinical trial evaluating MK-5172\/MK-8742 in genotype 1 infected patients (C-WORTHY Study) is scheduled to be presented at the 64th American Association for the Study of Liver Disease Annual Meeting, Washington D.C., Nov. 1-5. \u201cThe designation of MK-5172\/MK-8742 as a Breakthrough Therapy for chronic hepatitis C is an important milestone for Merck,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cThere remains significant unmet medical need in hepatitis C, and we are looking forward to","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:33+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131022006804r1&sid=hq1sf1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\/","name":"Merck Receives Breakthrough Therapy Designation for MK-5172\/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131022006804r1&sid=hq1sf1&distro=nx","datePublished":"2013-10-22T16:00:00+00:00","dateModified":"2023-03-22T04:04:33+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131022006804r1&sid=hq1sf1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131022006804r1&sid=hq1sf1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-breakthrough-therapy-designation-for-mk-5172-mk-8742-an-investigational-oral-combination-regimen-for-the-treatment-of-chronic-hepatitis-c-virus-hcv-infection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Receives Breakthrough Therapy Designation for MK-5172\/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"75676b46-ebd7-42d9-b383-efaef9c7fe9c","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742301\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742301"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}